Connecticut § 20-619a Biological product prescribing. Prescribing practitioner discussion with patient or representative. Documentation. Patient request to sign for delivery.

Connecticut Statutes

§ 20-619a — Biological product prescribing. Prescribing practitioner discussion with patient or representative. Documentation. Patient request to sign for delivery.

Connecticut § 20-619a

Title 20Professional and Occupational Licensing, Certification, Title Protection and Registration. Examining Boards

Ch. 400jPharmacy

This text of Connecticut § 20-619a (Biological product prescribing. Prescribing practitioner discussion with patient or representative. Documentation. Patient request to sign for delivery.) is published on Counsel Stack Legal Research, covering Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Conn. Gen. Stat. § 20-619a (2026).

Text

(a)Prior to prescribing a biological product, as defined in section 20-619, a prescribing practitioner shall discuss with the patient or a representative of the patient the treatment methods, alternatives to and risks associated with the use of such biological product. The prescribing practitioner shall inform the patient that he or she may opt to sign for delivery of the biological product. The prescribing practitioner shall document such discussion in the patient's medical record not later than twenty-four hours after such discussion has taken place. This section shall not apply to hospital inpatients, emergency care, F.D.A. approved vaccines, blood or blood components.

(b)The patient or a representative of the patient may make a request of the pharmacy that the patient or representati

Free access — add to your briefcase to read the full text and ask questions with AI

(a) Prior to prescribing a biological product, as defined in section 20-619, a prescribing practitioner shall discuss with the patient or a representative of the patient the treatment methods, alternatives to and risks associated with the use of such biological product. The prescribing practitioner shall inform the patient that he or she may opt to sign for delivery of the biological product. The prescribing practitioner shall document such discussion in the patient's medical record not later than twenty-four hours after such discussion has taken place. This section shall not apply to hospital inpatients, emergency care, F.D.A. approved vaccines, blood or blood components. (b) The patient or a representative of the patient may make a request of the pharmacy that the patient or representative be present to sign for delivery of the interchangeable biological product. The patient or representative of the patient may rescind such request at any time by notifying the pharmacy of such rescission.